Literature DB >> 8458338

In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides.

W B Offensperger1, S Offensperger, E Walter, K Teubner, G Igloi, H E Blum, W Gerok.   

Abstract

Antisense oligodeoxynucleotide strategies have been employed in a variety of eukaryotic systems both to understand normal gene function and to block gene expression. Pharmacologically, 'code blockers' are ideal agents for antitumour and antimicrobial treatments because of their specific mode of action. Here we report the inhibition of duck hepatitis B virus (DHBV) by antisense oligodeoxynucleotides in primary duck hepatocyte cultures in vitro as well as in DHBV-infected Pekin ducks in vivo. The most effective antisense oligodeoxynucleotide was directed against the 5' region of the pre-S gene and resulted in a complete inhibition of viral replication and gene expression in vitro and in vivo. These results demonstrate the application of antisense oligodeoxynucleotides in vivo and exemplify their potential as human antiviral therapeutics.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8458338      PMCID: PMC413330          DOI: 10.1002/j.1460-2075.1993.tb05767.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  39 in total

1.  Inhibition of proliferation by c-myb antisense oligodeoxynucleotides in colon adenocarcinoma cell lines that express c-myb.

Authors:  C Melani; L Rivoltini; G Parmiani; B Calabretta; M P Colombo
Journal:  Cancer Res       Date:  1991-06-01       Impact factor: 12.701

2.  Sulfated polyanions do not inhibit duck hepatitis B virus infection.

Authors:  W B Offensperger; S Offensperger; E Walter; H E Blum; W Gerok
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

Review 3.  Inhibition of protooncogene expression by antisense oligodeoxynucleotides: biological and therapeutic implications.

Authors:  B Calabretta
Journal:  Cancer Res       Date:  1991-09-01       Impact factor: 12.701

4.  Inhibition of duck hepatitis B virus infection by lysosomotropic agents.

Authors:  W B Offensperger; S Offensperger; E Walter; H E Blum; W Gerok
Journal:  Virology       Date:  1991-07       Impact factor: 3.616

5.  Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide.

Authors:  P C Zamecnik; M L Stephenson
Journal:  Proc Natl Acad Sci U S A       Date:  1978-01       Impact factor: 11.205

6.  Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival: comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides.

Authors:  J C Reed; C Stein; C Subasinghe; S Haldar; C M Croce; S Yum; J Cohen
Journal:  Cancer Res       Date:  1990-10-15       Impact factor: 12.701

7.  Specific inhibition of hepatitis B viral gene expression in vitro by targeted antisense oligonucleotides.

Authors:  G Y Wu; C H Wu
Journal:  J Biol Chem       Date:  1992-06-25       Impact factor: 5.157

8.  Mechanisms of the inhibition of reverse transcription by antisense oligonucleotides.

Authors:  C Boiziau; N T Thuong; J J Toulmé
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-15       Impact factor: 11.205

9.  Specific inhibition of transcription by triple helix-forming oligonucleotides.

Authors:  G Duval-Valentin; N T Thuong; C Hélène
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-15       Impact factor: 11.205

10.  Short modified antisense oligonucleotides directed against Ha-ras point mutation induce selective cleavage of the mRNA and inhibit T24 cells proliferation.

Authors:  T Saison-Behmoaras; B Tocqué; I Rey; M Chassignol; N T Thuong; C Hélène
Journal:  EMBO J       Date:  1991-05       Impact factor: 11.598

View more
  24 in total

Review 1.  Gene therapy of hepatic diseases: prospects for the new millennium.

Authors:  K Shetty; G Y Wu; C H Wu
Journal:  Gut       Date:  2000-01       Impact factor: 23.059

2.  Target site search and effective inhibition of leukaemic cell growth by a covalently closed multiple anti-sense oligonucleotide to c-myb.

Authors:  I J Moon; Y Lee; C S Kwak; J H Lee; K Choi; A D Schreiber; J G Park
Journal:  Biochem J       Date:  2000-03-01       Impact factor: 3.857

Review 3.  Preclinical and clinical pharmacology of antisense oligonucleotides.

Authors:  E G Marcusson; B R Yacyshyn; W R Shanahan; N M Dean
Journal:  Mol Biotechnol       Date:  1999-08       Impact factor: 2.695

Review 4.  Molecular strategies for interrupting arthropod-borne virus transmission by mosquitoes.

Authors:  C D Blair; Z N Adelman; K E Olson
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

Review 5.  Gene therapeutic approaches to inhibit hepatitis B virus replication.

Authors:  Maren Gebbing; Thorsten Bergmann; Eric Schulz; Anja Ehrhardt
Journal:  World J Hepatol       Date:  2015-02-27

Review 6.  Gene therapy for infectious diseases.

Authors:  B A Bunnell; R A Morgan
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

7.  Gene therapy in gastroenterology.

Authors:  H S Pandha; N R Lemoine
Journal:  Gut       Date:  1996-02       Impact factor: 23.059

8.  Triplex-forming oligonucleotides trigger conformation changes of a target hairpin sequence.

Authors:  E Brossalina; E Demchenko; Y Demchenko; V Vlassov; J J Toulmé
Journal:  Nucleic Acids Res       Date:  1996-09-01       Impact factor: 16.971

9.  Oligodeoxynucleotides enhance lipopolysaccharide-stimulated synthesis of tumor necrosis factor: dependence on phosphorothioate modification and reversal by heparin.

Authors:  G Hartmann; A Krug; K Waller-Fontaine; S Endres
Journal:  Mol Med       Date:  1996-07       Impact factor: 6.354

10.  Inhibition of duck hepatitis B virus replication by 2',3'-dideoxy-3'-fluoroguanosine in vitro and in vivo.

Authors:  P Hafkemeyer; A Keppler-Hafkemeyer; M A al Haya; M von Janta-Lipinski; E Matthes; C Lehmann; W B Offensperger; S Offensperger; W Gerok; H E Blum
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.